Related Experiment Videos
Low frequency of CDKN2 mutation in endometrial carcinomas
S L Peiffer1, D Bartsch, A J Whelan
1Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Molecular Carcinogenesis
|August 1, 1995
Summary
The CDKN2 gene, crucial for regulating cell division, showed alterations in some endometrial tumors. Researchers investigated its role in endometrial cancer development, finding mutations and deletions in a subset of samples.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The CDKN2 gene encodes the p16 protein, an inhibitor of cyclin D/cyclin-dependent kinase 4 complexes.
- While CDKN2 mutations/deletions are common in cell lines, their frequency in primary tumors is lower.
- Understanding CDKN2's role in endometrial cancer is important for tumorigenesis research.
Purpose of the Study:
- To investigate the role of the CDKN2 gene in endometrial tumorigenesis.
- To determine the frequency of CDKN2 alterations in endometrial carcinomas.
Main Methods:
- Examined 34 endometrial tumor samples for loss of heterozygosity at chromosome 9p21 using flanking markers.
- Assessed CDKN2 gene mutation frequency via single-strand conformation variant analysis and direct sequencing.
Main Results:
- Loss of 9p21 sequences was observed in three out of 34 tumors.
- Point mutations in CDKN2 were identified in two samples.
- One sample exhibited both loss of 9p21 and a CDKN2 point mutation.
Conclusions:
- CDKN2 alterations occur at a low frequency in primary endometrial carcinomas.
- These findings suggest a potential, albeit infrequent, role for CDKN2 in endometrial cancer development.